www.fdanews.com/articles/196974-pfizer-and-biontech-start-covid-19-vaccine-trial-in-us
![IV patient and doctor](https://www.fdanews.com/ext/resources/test/Drug-Images4/IV-blood-patient-nurse-doctor.gif?t=1585694898&width=430)
Pfizer and BioNTech Start COVID-19 Vaccine Trial in U.S.
May 6, 2020
Pfizer and BioNTech have started a U.S. trial of COVID-19 vaccine candidates at the NYU Grossman School of Medicine and the University of Maryland School of Medicine.
The phase 1/2 study will assess the safety, immunogenicity and optimal dose of four mRNA vaccine candidates in a single, continuous trial. The first stage will enroll up to 360 healthy subjects between the ages of 18-55 and 65-85 years of age.
The drugmakers are also conducting the trial in Germany — the first COVID-19 vaccine trial in that country.